Douglas J. Sheffler Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center Sanford Burnham Prebys Medical Discovery Institute Biography Publications Institution JoVE Articles Douglas J. Sheffler has not added a biography. If you are Douglas J. Sheffler and would like to personalize this page please email our Author Liaison for assistance. Publications A Cellular Target Engagement Assay for the Characterization of SHP2 (PTPN11) Phosphatase Inhibitors The Journal of Biological Chemistry. Feb, 2020 | Pubmed ID: 31953320 A Combination of Flow and Batch Mode Processes for the Efficient Preparation of MGlu Receptor Negative Allosteric Modulators (NAMs) Tetrahedron. Jun, 2018 | Pubmed ID: 30705468 Metabotropic Glutamate Receptor 5 As a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy Biological Psychiatry. 06, 2018 | Pubmed ID: 29628194 Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. Dec, 2017 | Pubmed ID: 28664928 Synthesis and Preliminary Studies of a Novel Negative Allosteric Modulator, 7-((2,5-Dioxopyrrolidin-1-yl)methyl)-4-(2-fluoro-4-[C]methoxyphenyl) Quinoline-2-carboxamide, for Imaging of Metabotropic Glutamate Receptor 2 ACS Chemical Neuroscience. 09, 2017 | Pubmed ID: 28565908 Screening for Small Molecule Inhibitors of Statin-Induced APP C-terminal Toxic Fragment Production Frontiers in Pharmacology. 2017 | Pubmed ID: 28261092 Bewertung des zellulären Zielengagements durch SHP2 (PTPN11) Phosphatase-Inhibitoren Lester J. Lambert1, Celeste Romero1, Douglas J. Sheffler1, Maria Celeridad1, Nicholas D. P. Cosford1, Lutz Tautz1 1Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute JoVE 61457 Cancer Research
Bewertung des zellulären Zielengagements durch SHP2 (PTPN11) Phosphatase-Inhibitoren Lester J. Lambert1, Celeste Romero1, Douglas J. Sheffler1, Maria Celeridad1, Nicholas D. P. Cosford1, Lutz Tautz1 1Cancer Metabolism & Signaling Networks Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute JoVE 61457 Cancer Research